KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Interest Expenses data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Interest Expenses changed 0.04% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $11.1 million, changed 0.02%, while the annual FY2025 figure was $11.1 million, 0.02% changed from the prior year.
  • Interest Expenses reached $2.8 million in Q4 2025 per AQST's latest filing, roughly flat from $2.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.8 million in Q3 2021 and bottomed at $1.3 million in Q3 2023.
  • Average Interest Expenses over 5 years is $2.3 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: plummeted 41.4% in 2022, then skyrocketed 121.34% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $1.7 million in 2021, then decreased by 5.39% to $1.6 million in 2022, then skyrocketed by 37.76% to $2.3 million in 2023, then grew by 22.26% to $2.8 million in 2024, then fell by 0.04% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.8 million in Q2 2025.